Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Equillium Inc (EQ)
NASDAQ:EQ
Holding EQ?
Track your performance easily
EQ Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.48 - $3.25
Previous Close$0.74
Volume65.19K
Average Volume (3M)184.40K
Market Cap
$27.01M
Enterprise Value-$6.47M
Total Cash (Recent Filing)$33.30M
Total Debt (Recent Filing)$609.00K
Price to Earnings (P/E)―
Beta1.83
Next Earnings
Mar 26, 2025EPS Estimate
-$0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding35,430,763
10 Day Avg. Volume142,690
30 Day Avg. Volume184,395
Standard Deviation0.45
R-Squared0.05
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)1.14
Price to Sales (P/S)0.58
Price to Cash Flow (P/CF)8.50
P/FCF Ratio9.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.15
Enterprise Value/Gross Profit-0.18
Enterprise Value/Ebitda0.84
Forecast
1Y Price Target
$2.50Price Target Upside227.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Equillium News
PremiumCompany Announcements
Equillium’s Q3 Financials and Clinical Progress in Focus
PremiumPre-Earnings
Is EQ a Buy, Before Earnings?
Bulls Say, Bears Say
Bulls Say
Clinical TrialsEquillium received a positive recommendation from the Independent Data Monitoring Committee based on its review of the interim results from the Phase 3 EQUATOR study evaluating itolizumab in subjects with acute graft-vs.-host disease.
Financial HealthEquillium reached the end of 2Q24 with approximately $33.3M in cash, cash equivalents and short-term investments; this balance sheet strength is relatively unchanged vs. the $32.3M reported as of end-1Q24.
Partnerships And LicensingIf Ono Pharmaceutical Co. Ltd. exercises its option on itolizumab, this would result in a payment of ¥5B—roughly $32.2M based on recent exchange rates—and significantly improve Equillium's balance sheet strength.
Bears Say
Financial StrategyEQ has paused further activities on earlier pipeline assets to conserve cash, including EQ101 in alopecia areata and the preclinical oral peptide EQ302.
Risk FactorsRisks include, but are not limited to: delays in generating clinical data with itolizumab, refusal by Ono to exercise its option on itolizumab, failure to obtain approval for itolizumab, clinical setbacks with other pipeline programs, notably EQ-101 and EQ-102, and possible medium-term dilution risk.
Strategic DecisionsOno Pharmaceutical decided not to exercise its option to acquire itolizumab based on strategic reasons.
---
Ownership Overview
40.26% Insiders
2.92% Mutual Funds
14.57% Other Institutional Investors
39.84% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EQ FAQ
What was Equillium Inc’s price range in the past 12 months?
Equillium Inc lowest stock price was $0.48 and its highest was $3.25 in the past 12 months.
What is Equillium Inc’s market cap?
Currently, no data Available
When is Equillium Inc’s upcoming earnings report date?
Equillium Inc’s upcoming earnings report date is Mar 26, 2025 which is in 119 days.
How were Equillium Inc’s earnings last quarter?
Equillium Inc released its earnings results on Nov 13, 2024. The company reported $0 earnings per share for the quarter, missing the consensus estimate of $0.018 by -$0.018.
Is Equillium Inc overvalued?
According to Wall Street analysts Equillium Inc’s price is currently Undervalued.
Does Equillium Inc pay dividends?
Equillium Inc does not currently pay dividends.
What is Equillium Inc’s EPS estimate?
Equillium Inc’s EPS estimate is -$0.29.
How many shares outstanding does Equillium Inc have?
Equillium Inc has 35,430,763 shares outstanding.
What happened to Equillium Inc’s price movement after its last earnings report?
Equillium Inc reported an EPS of $0 in its last earnings report, missing expectations of $0.018. Following the earnings report the stock price went down -12.821%.
Which hedge fund is a major shareholder of Equillium Inc?
Among the largest hedge funds holding Equillium Inc’s share is Cota Capital Management, LLC. It holds Equillium Inc’s shares valued at 468K.
---
Equillium Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.50 (227.98% Upside)
$2.50 (227.98% Upside)
Crowd Wisdom
Positive
Last 7 Days ▼ 2.4%
Last 30 Days ▲ 5.3%
Last 30 Days ▲ 5.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
45.38%
12-Months-Change
Fundamentals
Return on Equity
-19.52%
Trailing 12-Months
Asset Growth
-37.61%
Trailing 12-Months
Company Description
Equillium Inc
Equillium, Inc. is a biotechnology company, which engages in the development of products for severe immuno-inflammatory disorders with high unmet medical need. Its product pipeline include EQ001, is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly on March 16, 2017 and is headquartered in La Jolla, CA.
---
EQ Stock 12 Month Forecast
Average Price Target
$2.50
▲(227.98% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Arcutis Biotherapeutics
―
Immatics
―
Kiniksa Pharmaceuticals
―
Best Analysts Covering EQ
1 Year
1 Year Success Rate
6/20 ratings generated profit
1 Year Average Return
-6.31%
reiterated a buy rating 27 days ago
Copying Thomas Smith's trades and holding each position for 1 Year would result in 30.00% of your transactions generating a profit, with an average return of -6.31% per trade.
---